Cargando…
Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia
BACKGROUND: Older patients with acute myeloid leukemia are particularly difficult to treat, as they have a high risk of comorbidities, poor performance status and less tolerability to chemotherapy, as well as a more aggressive disease biology, responsible for the resistance to treatment. There is a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517609/ https://www.ncbi.nlm.nih.gov/pubmed/31084767 http://dx.doi.org/10.1016/j.htct.2018.09.001 |